{
    "clinical_study": {
        "@rank": "23495", 
        "arm_group": [
            {
                "arm_group_label": "Abametapir lotion 0.74% w/w", 
                "arm_group_type": "Experimental", 
                "description": "Applied 0.2 mL topically under occlusive condition"
            }, 
            {
                "arm_group_label": "Vehicle lotion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Applied 0.2 mL topically under occlusive condition"
            }, 
            {
                "arm_group_label": "Sodium Lauryl Sulfate", 
                "arm_group_type": "Other", 
                "description": "Positive control applied 0.2 mL topically under occlusive condition"
            }, 
            {
                "arm_group_label": "Saline 0.9%", 
                "arm_group_type": "Other", 
                "description": "Negative control applied 0.2 mL topically under occlusive condition"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the irritation potential of repeat applications of\n      abametapir lotion on normal skin."
        }, 
        "brief_title": "Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Head Lice", 
        "detailed_description": {
            "textblock": "This will be a randomized, evaluator-blind, single-center, controlled, within-subject\n      comparison study of the investigational products (abametapir lotion) and its vehicle lotion\n      and positive and negative controls under occlusive conditions in healthy volunteers.  All\n      subjects will have the investigational product (abametapir lotion), the vehicle product, the\n      positive control patch, and negative control patch applied to 4 randomly assigned, adjacent\n      skin sites on the infrascapular area of their back, for the purpose of determining\n      irritation potential.\n\n      The investigational products, vehicle, and controls will be applied to one side of the\n      infrascapular area of the back.  Evaluation of dermal reactions at the application sites\n      will be assessed clinically using a visual scale that rates the degree of erythema, edema,\n      and other signs of cutaneous irritation (see Section 3.5.5).\n\n      A total of 21 applications of each product will be made."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or\n             older;\n\n          2. In the case of females of childbearing potential, are using an acceptable form of\n             birth control (oral/implant/injectable/transdermal contraceptives, intrauterine\n             device, condom with spermicide, diaphragm with spermicide, abstinence, partner's\n             vasectomy).  Abstinence or vasectomized partner are acceptable if the female subject\n             agrees to implement one of the other acceptable methods of birth control if her\n             lifestyle/partner changes;\n\n          3. If female of childbearing potential, have a negative urine pregnancy test (UPT) at\n             Day 1, and are willing to submit to a pregnancy test at the end of study (EOS);\n\n          4. Are free of any systemic or dermatologic disorder, which, in the opinion of the\n             investigator, will interfere with the study results or increase the risk of adverse\n             events;\n\n          5. Are of any skin type or race, providing the skin pigmentation will allow discernment\n             of erythema;\n\n          6. Complete a patch study Medical Screening form as well as a Medical Personal History\n             form; and\n\n          7. Read, understand, and provide signed informed consent.\n\n        Exclusion Criteria:\n\n          1. Have any visible skin disease at the application site which, in the opinion of the\n             investigative personnel, will interfere with the evaluation of the test site\n             reaction;\n\n          2. Are not willing to refrain from using topical/systemic analgesics such as aspirin\n             (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72\n             hours prior to and during the study (occasional use of acetaminophen will be\n             permitted);\n\n          3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during\n             the study, or systemic/topical antihistamines for 72 hours prior to and during the\n             study;\n\n          4. Are using medication which, in the opinion of the investigative personnel, will\n             interfere with the study results, including anti-inflammatory medications;\n\n          5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams,\n             ointments, lotions, or similar products on the back during the study;\n\n          6. Have psoriasis and/or active atopic dermatitis/eczema;\n\n          7. Are females who are pregnant, plan to become pregnant during the study, or are\n             breast-feeding a child;\n\n          8. Have a known sensitivity to constituents present in the material being evaluated;\n\n          9. Have damaged skin in or around the test sites, including sunburn, excessively deep\n             tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other\n             disfigurations of the test site\n\n         10. Have received treatment for any type of internal cancer within 5 years prior to study\n             entry;\n\n         11. Have a history of, or are currently being treated for skin cancer;\n\n         12. Are currently participating in any other clinical trial,\n\n         13. Have any known sensitivity to adhesives; and/or\n\n         14. Have received any investigational treatment(s) within 4 weeks prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061813", 
            "org_study_id": "Ha03-007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abametapir lotion 0.74% w/w", 
                "description": "applied 0.2 mL topically under occlusive condition", 
                "intervention_name": "Abametapir Lotion 0.74% w/w", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sodium Lauryl Sulfate", 
                "description": "Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.", 
                "intervention_name": "Sodium Lauryl Sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline 0.9%", 
                "description": "A solution of 0.9% saline for topical administration, applied 21 times over consecutive days  under occlusive conditions, will serve as a negative control", 
                "intervention_name": "Saline 0.9%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle lotion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Hatchtech", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paramus", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07652"
                }, 
                "name": "TKL Reserach Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Abametapir Lotion in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design", 
        "overall_official": {
            "affiliation": "TKL Research, Inc.", 
            "last_name": "Jonathan Dosik", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The evaluation of irritation is based on Modified Berger procedure and is accepted as standard methodology for assessment of cumulative irritation potential. The assessment of all patch sites for irritation symptoms will be visually assessed by a trained evaluator using the response symbols and numerical equivalents (0-7) and effects on superficial layers of the skin symbols (A-H) will be done at daily basis from baseline through Day 21 visit.", 
            "measure": "Evaluate the potential of abametapir lotion to cause irritation after repeated topical application to the healthy skin of humans under controlled conditions.", 
            "safety_issue": "Yes", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061813"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hatchtech Pty Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hatchtech Pty Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}